Emmanuel A Ojo-Amaize and Howard B Cottam
Parkinson’s disease (PD) is a common neurodegenerative disorder belonging to a heterogeneous group of disorders with α-synuclein pathology and PD dementia. Hypoestoxide is being developed to combat microgliosis, astrogliosis, loss of dopaminergic neurons, motor behavioral deficits and α-synuclein pathology in PD.